Ⅲ期非小细胞肺癌病人新辅助化疗联合免疫治疗后无病生存的影响因素分析

doi:10.3969/j.issn.1005-6483.2023.07.008

临床外科杂志 ›› 2023, Vol. 31 ›› Issue (7): 626-629.doi: 10.3969/j.issn.1005-6483.2023.07.008

Ⅲ期非小细胞肺癌病人新辅助化疗联合免疫治疗后无病生存的影响因素分析

441021 湖北文理学院附属医院襄阳市中心医院心胸外科

收稿日期:2022-08-24 接受日期:2022-08-24 出版日期:2023-07-20 发布日期:2023-07-20
通讯作者: 夏世辉，Email：xsh7000@163.com
基金资助:
湖北省自然基金资助项目(2017CCV063)

Influencing factors of disease-free survival in patients with stage Ⅲ non-small cell lung cancer after neoadjuvant chemotherapy combined with immunotherapy

Department of Cardiothoracic Surgery,Affiliated Hospital of Hubei University of Arts and Science,Xiangyang Central Hospital,Hubei，Xiangyang 441021,China

Received:2022-08-24 Accepted:2022-08-24 Online:2023-07-20 Published:2023-07-20

摘要/Abstract

摘要： 目的探讨Ⅲ期非小细胞肺癌(NSCLC)病人新辅助化疗联合免疫治疗后无病生存的影响因素。方法我院2014年5月~2019年5月接受新辅助化疗联合免疫治疗后行根治术的Ⅲ期NSCLC病人200例，在新辅助化疗联合免疫治疗后随访3年，根据3年无病生存情况分为无病生存组(76例)及非无病生存组(124例)，采用Kaplan-Meier法分析无病生存期(DFS)，采用Cox回归模型分析影响NSCLC新辅助化疗联合免疫治疗后行根治术病人无病生存的因素。结果 200例病人3年无病生存76例，无病生存率为38.00%，中位DFS为21个月。无病生存组与非无病生存组吸烟史、分化程度、肿瘤直径、EGFR基因突变、ALK基因表达、新辅助化疗联合免疫治疗的疗效及术后辅助化疗等比较，差异有统计学意义(P＜0.05)。Cox回归模型分析显示，吸烟史(OR=2.016，P=0.004)、低分化(OR=2.125，P=0.001)、肿瘤直径＞3cm(OR=1.958，P=0.007)、EGFR基因突变(OR=2.305，P=0.002)、ALK基因阳性表达(OR=2.450，P=0.004)、新辅助化疗联合免疫治疗后未缓解(OR=1.820，P=0.005)均为新辅助化疗联合免疫治疗后行NSCLC根治术病人无病生存的危险因素，术后辅助化疗(OR=1.728，P=0.006)为新辅助化疗联合免疫治疗后行NSCLC根治术病人无病生存的保护因素。结论 NSCLC新辅助化疗联合免疫治疗后行根治术病人无病生存与吸烟史、分化程度、肿瘤直径、EGFR基因突变、ALK基因表达、新辅助化疗联合免疫治疗的疗效及术后辅助化疗等因素有关。

关键词: 非小细胞肺癌, Ⅲ期, 新辅助化疗, 免疫治疗, 无病生存

Abstract: Objective To explore the influencing factors of disease-free survival(DFS) in patients with stage Ⅲ non-small cell lung cancer (NSCLC) after neoadjuvant chemotherapy combined with immunotherapy. Methods A total of 200 patients with stage Ⅲ NSCLC undergoing radical operation after neoadjuvant chemotherapy combined with immunotherapy in the hospital were enrolled between May 2014 and May 2019.All were followed up for 3 years after neoadjuvant chemotherapy combined with immunotherapy.According to 3-year DFS,they were divided into DFS group (n=76) and non-DFS group (n=124).DFS was analyzed by Kaplan-Meier method,and its influencing factors were analyzed by Cox regression model. Results In the 200 patients,there were 96 cases (38.00%) with 3-year DFS,and the median DFS was 21 months.The differences in smoking history,differentiation degree,tumor diameter,EGFR gene mutation,expression of ALK gene,curative effect of neoadjuvant chemotherapy combined with immunotherapy,and postoperative adjuvant chemotherapy between the two groups were statistically significant (P<0.05).The analysis of Cox regression model showed that smoking history (OR=2.016,P=0.004),low differentiation (OR=2.125,P=0.001),tumor diameter >3 cm (OR=1.958,P=0.007),EGFR gene mutation (OR=2.305,P=0.002),positive expression of ALK gene (OR=2.450,P=0.004) and non-remission after neoadjuvant chemotherapy combined with immunotherapy (OR=1.820,P=0.005) were risk factors of DFS,while postoperative adjuvant chemotherapy (OR=1.728,P=0.006) was a protective factor. Conclusion In patients with stage III NSCLC undergoing radical operation after neoadjuvant chemotherapy combined with immunotherapy,DFS is related to smoking history,differentiation degree,tumor diameter,EGFR gene mutation,expression of ALK gene,curative effect of neoadjuvant chemotherapy combined with immunotherapy and postoperative adjuvant chemotherapy.

Key words: non-small cell lung cancer, stage Ⅲ, neoadjuvant chemotherapy, immunotherapy, disease-free survival

李大伟夏世辉. Ⅲ期非小细胞肺癌病人新辅助化疗联合免疫治疗后无病生存的影响因素分析[J]. 临床外科杂志, 2023, 31(7): 626-629.

LI Dawei, XIA Shihui. Influencing factors of disease-free survival in patients with stage Ⅲ non-small cell lung cancer after neoadjuvant chemotherapy combined with immunotherapy[J]. JOURNAL OF CLINICAL SURGERY, 2023, 31(7): 626-629.

参考文献

相关文章 15

[1]	陈星张楠陈树兴. 荧光胸腔镜下动脉流域亚肺叶切除术在早期周围型非小细胞肺癌中的应用[J]. 临床外科杂志, 2023, 31(6): 557-561.
[2]	曾强张宇陈辉石珂周丽. 富含亮氨酸的α2糖蛋白1通过RUNX1/OPN信号调节非小细胞肺癌细胞的增殖、迁移和侵袭 [J]. 临床外科杂志, 2023, 31(6): 562-567.
[3]	陈勇伟李昊黄力陈从波王黎姚启盛. 新辅助化疗联合经尿道膀胱肿瘤电切术对膀胱癌病人肿瘤直径、尿液膀胱肿瘤抗原水平及复发率的影响[J]. 临床外科杂志, 2023, 31(2): 152-155.
[4]	陈健朱余明. 非小细胞肺癌术后辅助治疗研究进展[J]. 临床外科杂志, 2022, 30(8): 707-713.
[5]	刘凯李勃吴向天明怀德. 二甲双胍通过LncRNA-H19抑制非小细胞肺癌A549迁移及侵袭的机制研究[J]. 临床外科杂志, 2022, 30(8): 719-721.
[6]	牛磊霍承瑜刘宗志王兵. 两种入路单孔胸腔镜下肺叶切除术对非小细胞肺癌病人术后康复进程、肺功能及内环境指标的影响[J]. 临床外科杂志, 2022, 30(8): 722-726.
[7]	李新盖慧荣宋蕾张忠法. 长链非编码RNA SRGAP3-AS2异常表达通过Janus激酶信号调节非小细胞肺癌侵袭和迁移[J]. 临床外科杂志, 2022, 30(8): 727-730.
[8]	王永富吴远林解少强沈长军. 电视胸腔镜解剖性肺段切除术治疗早期非小细胞肺癌疗效及对血清C反应蛋白、白细胞介素1β、白细胞介素-6、肿瘤坏死因子-α水平的影响分析[J]. 临床外科杂志, 2022, 30(8): 731-734.
[9]	田文泽熊新魁徐达夫胡忠吾蒋超尤振兵赵建强徐克平 . 卡瑞利珠单抗联合化疗在局部晚期食管鳞癌转化治疗中的应用[J]. 临床外科杂志, 2022, 30(8): 741-743.
[10]	李栋梁罗建飞. 局部进展期Siewert Ⅱ/Ⅲ型食管胃结合部腺癌新辅助化疗后腹腔镜手术及开放手术的临床对比分析[J]. 临床外科杂志, 2022, 30(5): 429-432.
[11]	阮添李昌盛杨泽天周雪峰王乐. 内脏胸膜侵犯对术后ⅢA/N2期非小细胞肺癌病人生存的影响：SEER数据库分析[J]. 临床外科杂志, 2022, 30(5): 448-452.
[12]	叶彬向秋金文杰. 叉头框蛋白Q1和细胞周期蛋白D1在非小细胞肺癌组织中的表达与临床病理特征及预后的关系[J]. 临床外科杂志, 2022, 30(5): 453-458.
[13]	金成龙张建国. 乳腺癌新辅助化疗后前哨淋巴结活检的研究进展[J]. 临床外科杂志, 2022, 30(4): 386-389.
[14]	朱行伍邱麦轩李静. 晚期胆道系统恶性肿瘤的免疫治疗进展[J]. 临床外科杂志, 2022, 30(11): 1098-1100.
[15]	舒凯雷霆朱洪涛黄逸民刘俊峰. 脑胶质瘤免疫治疗进展与展望[J]. 临床外科杂志, 2022, 30(10): 917-919.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Ⅲ期非小细胞肺癌病人新辅助化疗联合免疫治疗后无病生存的影响因素分析

Influencing factors of disease-free survival in patients with stage Ⅲ non-small cell lung cancer after neoadjuvant chemotherapy combined with immunotherapy

PDF (PC)

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

本文评价

推荐阅读 0